Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1 Study of Venetoclax/Azacitidine or Venetoclax in Combination With Ziftomenib or Standard Induction Cytarabine/Daunorubicin (7+3) Chemotherapy in Combination With Ziftomenib for the Treatment of Patients With Acute Myeloid Leukemia

NCT05735184 is registered in ClinicalTrials.gov with Kura Oncology, Inc. as lead sponsor.

NCT NCT05735184
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05735184 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1 Study of Venetoclax/Azacitidine or Venetoclax in Combination With Ziftomenib or Standard Induction Cytarabine/Daunorubicin (7+3) Chemotherapy in Combination With Ziftomenib for the Treatment of Patients With Acute Myeloid Leukemia
Lead sponsor
Kura Oncology, Inc.
Phase
Phase 1
Overall status
Recruiting
Start date
July 18, 2023
Completion date
April 30, 2030
Enrollment
420 (estimated)
Sites
44

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia, acute myeloid leukemia recurrent, acute myeloid leukemia, in relapse, aml with mutated npm1, kmt2ar, mixed lineage leukemia gene mutation, myeloid sarcoma, npm1 mutation, nucleophosmin 1-mutated acute myeloid leukemia, refractory aml